Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-02-09
2002-12-10
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S307000, C514S311000, C546S018000, C546S112000, C546S159000
Reexamination Certificate
active
06492378
ABSTRACT:
This invention relates to novel compounds, to processes for preparing them, and to their use as therapeutic agents.
U.S. Pat. No. 4,022,900 (Marion) discloses benzamido-tetrahydroisoquinolines having anti-hypertensive and vasodilator properties.
PCT/GB98/00781 (SmithKline Beecham), unpublished at the filing date of this application, discloses that benzamide compounds of formula (A) below possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, and related depression disorders.
where;
R
1
is hydrogen, C
1-6
alkyl (optionally substituted by hydroxy or C
1-4
alkoxy), C
1-6
alkenyl, C
1-6
alkynyl, C
1-6
alkylCO—, formyl, CF
3
CO— or C
1-6
alkylSO
2
—,
R
2
is hydrogen or up to three substituents selected from halogen, NO
2
, CN, N
3
, CF
3
O—, CF
3
S—, CF
3
CO—, trifluoromethyldiazirinyl, C
1-6
alkyl, C
1-6
alkenyl, C
1-6
alkynyl, C
1-6
perfluoroalkyl, C
3-6
cycloalkyl, C
3-6
cycloalkyl-C
1-4
alkyl-, C
1-6
alkylO—, C
1-6
alkylCO—, C
3-6
cycloalkylO—, C
3-6
cycloalkylCO—, C
3-6
cycloalkyl-C
1-4
alkylO—, C
3-6
cycloalkyl-C
1-4
alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C
1-4
alkyl-, C
1-6
alkylS—, C
1-6
alkylSO
2
—, (C
1-4
alkyl)
2
NSO
2
—, (C
1-4
alkyl)NHSO
2
—, (C
1-4
alkyl)
2
NCO—, (C
1-4
alkyl)NHCO— or CONH
2
;
or —NR
5
R
6
where R
5
is hydrogen or C
1-4
alkyl, and
R
6
is hydrogen, C
1-4
alkyl, formyl, —CO
2
C
1-4
alkyl or —COC
1-4
alkyl;
or two R
2
groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O; and
the two R
3
groups and the two R
4
groups are each independently hydrogen or C
1-6
alkyl or the two R
3
groups and/or the two R
4
groups together form a C
3-6
spiroalkyl group provided that at least one R
3
and R
4
group is not hydrogen.
It has now been surprisingly found that carboxamide compounds of formula (I) below possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression , panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
Accordingly, the present invention provides a compound of formula (I) or salts thereof or solvates thereof:
wherein:
R
1
is hydrogen, C
1-6
alkyl (optionally substituted by hydroxy or C
1-4
alkoxy), C
1-6
alkenyl, C
1-6
alkynyl, C
1-6
alkylCO—, formyl, CF
3
CO— or C
1-6
alkylSO
2
—;
R
2
is hydrogen or up to three substituents selected from halogen, NO
2
, CN, N
3
, CF
3
O—, CF
3
S—, CF
3
CO—, CF
3
SO
2
, trifluoromethyldiazirinyl, C
1-6
alkyl, C
1-6
alkenyl, C
1-6
alkynyl, C
1-6
perfluoroalkyl, C
3-6
cycloalkyl, C
3-6
cycloalkyl-C
1-4
alkyl-, C
1-6
alkylO—, C
1-6
alkylCO—, C
3-6
cycloalkylO—, C
3-6
cycloalkylCO—, C
3-6
cycloalkyl-C
1-4
alkylO—, C
3-6
cycloalkyl-C
1-4
alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C
1-4
alkyl-, C
1-6
alkylS—, C
1-6
alkylSO
2
—, (C
1-4
alkyl)
2
NSO
2
—,(C
1-4
alkyl)NHSO
2
—, (C
1-4
alkyl)
2
NCO—, (C
1-4
alkyl)NHCO— and CONH
2
; or —NR
5
R
6
where R
5
is hydrogen or C
1-4
alkyl, and R
6
is hydrogen, C
1-4
alkyl, formyl, —CO
2
C
1-4
alkyl or —COC
1-4
alkyl; or two R
2
groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O;
the two R groups, the two R
3
groups and the two R
4
groups are each independently hydrogen, C
1-6
alkyl, C
1-6
alkenyl, benzyl, or phenyl, or the two R groups and/or the two R
3
groups and/or the two R
4
groups together form a C
3-6
spiroalkyl group, provided that at least one R , R
3
or R
4
group is other than hydrogen; and
X is selected from the group consisting of hydrogen, halogen, cyano, CF
3
, alkyl and alkoxy;
provided that when X is hydrogen. the two R groups are not both hydrogen.
The compounds of this invention are typically isoquinolinyl-carboxamides, especially (tetrahydroisoquinolin-5-yl) and (tetrahydroisoquinolin-7-yl)carboxamides. The carboxamide moiety may be a benzamide. When two R
2
groups form a carbocyclic ring, this is typically a 5-7 membered ring, and the carboxamide moiety may be a naphthalene carboxamide or an indane or indanone carboxamide.
In the formula (I), alkyl groups, including alkyl groups that are part of other moieties, such as alkoxy or acyl, may be straight chain or branched. Phenyl groups, including phenyl groups that are part of other moieties, in R
2
may optionally be substituted with one or more independently selected halogen or C
1-6
alkyl, C
1-6
alkoxy or C
1-6
alkylcarbonyl.
Suitable C
3-6
cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Suitable halo substituents include fluoro, chloro, iodo and bromo.
It should be appreciated that compounds of the present invention possess chiral centres and as such may exist in different enantiomeric forms, the present invention extends to each enantiomeric form and mixtures thereof including diastereoisomers and racemates.
A preferred group of compounds of formula (I) have;
R as methyl or hydrogen; and/or
R
1
as hydrogen or methyl; and/or
R
2
as methyl, ethyl, iso-propyl, methoxy, ethoxy, iso-propoxy, bromo, chloro, fluoro, iodo, cyano, acetyl, CF
3
, or C
2
F
5
; and/or
R
3
as hydrogen, methyl, or spirocyclobutyl; and/or
R
4
as hydrogen, methyl, benzyl, allyl, phenyl, iso-butyl, or iso-propyl; and/or
X as hydrogen, chloro, bromo, methyl, or ethyl.
A further aspect of the invention provides a compound selected from the group consisting of;
N-(3,3-Dimethyl-1,2,3,4-tetrahydro-2-trifluoroacetyl-isoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydro-2-trifluoroacetyl-isoquinolin-7-yl)-3-cyano-4-iso-propylbenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydro-2-trifluoroacetylisoquinolin-7-yl)-3-chloro-4-iso-propyloxybenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydro-2-trifluoroacetylisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydro-2-trifluoroacetylisoquinolin-7-yl)-3-bromo-4-iso-propyloxybenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-trifluoromethylbenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-iso-propylbenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-iso-propyloxy-benzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-ethoxybenzamide;
N-(3,3-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-iso-propyloxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-cyano-4-iso-propyloxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-iso-propyloxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-bromo-4-ethoxy-2-methoxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-acetyl-4-iso-propyloxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-bromo-4-methoxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro4-methoxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-iodo-4-methoxybenzamide;
N-(2,4,4-Trimethyl-1,2,3,4-tetrahydroisoquinol
Harling John David
Heer Jag Paul
Thompson Mervyn
Desai Rita
Hall Linda E.
Kinzig Charles M.
Rotman Alan L.
SmithKline Beecham p.l.c.
LandOfFree
Substituted isoquinoline derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted isoquinoline derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted isoquinoline derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2958274